The Phase I study is testing a bispecific antibody, XmAb14045, in acute myeloid leukemia, under a partnership with Swiss drugmaker Novartis. Xencor's stock fell following the news.
The drugmaker said Monday that it had signed a deal with Teneobio to develop a BCMA-targeting bispecific antibody.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
CAR-Ts have generated excitement, but bispecific monoclonal antibodies may continue to have a competitive edge in some cases.